GlassScriptPhysician profile
Mudresh R Mehta
NPI 1982932083
$3,203.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $123 · 2021: $11.40 · 2022: $17.60 · 2023: $2,633 · 2024: $61.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,498 · Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,497.50 |
| Food and Beverage | $196.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,577.81 | 2023 | Calquence |
| Ipsen Biopharmaceuticals, INC | $123.24 | 2020 | |
| Genentech USA, INC. | $116.86 | 2019 | |
| Amgen INC. | $111.49 | 2019 | |
| Merck Sharp & Dohme LLC | $99.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $52.66 | 2019-2024 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $20.71 | 2024 | |
| Daiichi Sankyo INC. | $18.99 | 2023 | Enhertu |
| Celgene Corporation | $18.20 | 2023 | |
| Kite Pharma, INC. | $17.79 | 2023 | Yescarta |
| Novartis Pharmaceuticals Corporation | $17.60 | 2022 | |
| Abbvie INC. | $16.83 | 2019 | |
| Adc Therapeutics America, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mudresh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.